Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04388826 · ClinicalTrials.gov registry record · Phase 2
COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111
A Phase 2 study, sponsored by Veru.
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT04388826 is a Phase 2 study that has completed, run by Veru. The registered enrollment target is 39 participants.
The verdict
NCT04388826, a Phase 2 study, has completed, sponsored by Veru.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical ventilation, or ventilation with additional organ support (e.g., pressors, RRT, ECMO).
Interventions
- DRUG Veru-111
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2020-06-18 |
| Est. Completion | 2021-08-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04388826
The ClinicalTrials.gov registry entry for NCT04388826 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veru, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Veru-111 is the first listed.
NCT04388826 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04388826 about?
NCT04388826 is a clinical study titled "COVID-19 Treatment of Severe Acute Respiratory Syndrome With Veru-111". To demonstrate the efficacy of VERU-111 in the treatment of SARS-Cov-2 Infection by assessing its effect on the proportion of subjects that are alive without respiratory failure at Day 22. Respiratory failure is defined as non-invasive ventilation or high-flow oxygen, intubation and mechanical venti...
What is the current status of trial NCT04388826?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2020-06-18. Estimated completion is 2021-08-13.
What interventions are being tested in trial NCT04388826?
The interventions under investigation include: Veru-111 (DRUG).
Who is sponsoring clinical trial NCT04388826?
This trial is sponsored by Veru, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.